Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAW NASDAQ:EBIO NASDAQ:NEXI NASDAQ:NTHI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.01$0.01$0.06▼$0.33N/AN/A34,287 shsN/AEBIOEleven Biotherapeutics$0.00$0.62▼$3.50N/AN/A2.86 million shs15.58 million shsNEXINexImmune$0.00$0.00$0.00▼$1.18N/A2.046,143 shs1 shsNTHINeonc Technologies$5.43+6.3%$5.11$3.20▼$25.00N/AN/A164,568 shs77,351 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%0.00%+276.92%+92.16%-75.50%NEXINexImmune0.00%0.00%+100.00%+100.00%-99.98%NTHINeonc Technologies+6.68%+4.29%+11.33%-30.66%+510,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AEBIOEleven BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AEBIOEleven Biotherapeutics 0.00N/AN/AN/ANEXINexImmune 0.00N/AN/AN/ANTHINeonc Technologies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AEBIOEleven BiotherapeuticsN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/ANTHINeonc Technologies$79.99KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AEBIOEleven BiotherapeuticsN/AN/A0.00N/AN/AN/AN/AN/AN/ANEXINexImmune-$32.34M-$18.54N/A∞N/AN/A-534.32%-213.72%N/ANTHINeonc TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AEBIOEleven BiotherapeuticsN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEHAWAesther Healthcare AcquisitionN/AN/AN/AEBIOEleven BiotherapeuticsN/AN/AN/ANEXINexImmuneN/A0.660.66NTHINeonc TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/AEBIOEleven Biotherapeutics13.96%NEXINexImmune9.85%NTHINeonc TechnologiesN/AInsider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/AEBIOEleven Biotherapeutics28.70%NEXINexImmune14.90%NTHINeonc TechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableEBIOEleven BiotherapeuticsN/AN/AN/AOptionableNEXINexImmune61.40 million1.19 millionNot OptionableNTHINeonc Technologies8N/AN/AN/AEBIO, AEHAW, NTHI, and NEXI HeadlinesRecent News About These CompaniesNew to The Street's Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM IncorporationAugust 11 at 10:52 PM | eagletribune.comENeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM IncorporationAugust 11 at 9:00 AM | globenewswire.comNeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and LeukemiaAugust 7, 2025 | globenewswire.comNTHI - NeOnc Technologies Holdings Inc Financials | MorningstarAugust 6, 2025 | morningstar.comMNeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain CancerAugust 4, 2025 | globenewswire.comNeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of DirectorsJuly 30, 2025 | globenewswire.comNeOnc Technologies Holdings, Inc.: NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar InvestmentJuly 30, 2025 | finanznachrichten.deAI and biotech take on brain cancerJuly 30, 2025 | finance.yahoo.comNeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar InvestmentJuly 30, 2025 | finance.yahoo.comNeOnc Technologies to Participate at the BTIG Virtual Biotechnology ConferenceJuly 28, 2025 | tmcnet.comNeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar InvestmentJuly 24, 2025 | finance.yahoo.comNeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on ...July 24, 2025 | bakersfield.comBCORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.July 23, 2025 | globenewswire.comNeOnc Technologies Secures Board Approval for $50 Million Strategic ...July 12, 2025 | seekingalpha.comNeOnc Technologies Holdings, Inc. Secures Board Approval for ... - NasdaqJuly 12, 2025 | nasdaq.comNeOnc Technologies Announces UAE Investment PartnershipJuly 11, 2025 | msn.comNeOnc Technologies Holdings Inc. (NTHI) Stock Price Today - WSJJuly 10, 2025 | wsj.comNeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar InvestmentJuly 10, 2025 | finance.yahoo.comNeOnc Technologies stock soars on planned $50M UAE investment dealJuly 10, 2025 | uk.investing.comNeOnc Technologies Holdings, Inc. Forms New UAE-Based Investment Platform NuroMENA for Clinical Trials in MENA Region - NasdaqJuly 10, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEBIO, AEHAW, NTHI, and NEXI Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.0098 0.00 (0.00%) As of 08/8/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.Eleven Biotherapeutics NASDAQ:EBIOSesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.NexImmune NASDAQ:NEXI$0.0002 0.00 (0.00%) As of 08/11/2025NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Neonc Technologies NASDAQ:NTHI$5.43 +0.32 (+6.26%) As of 04:00 PM EasternNeonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's White House Reset: From Political Storm to a Clearer Sky AST SpaceMobile on Track for Explosive Upside Oklo’s Stock Is Set up for a Correction—Buy It When It Bounces If Qualcomm Holds $145, Its Next Move Could Be Massive Alphabet Reclaims $200 Threshold—Bull Run Reignited? NFL and WWE Land on ESPN—The Impact on Disney and TKO Stocks Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside Apple & Trump: $100B Investment, Tariffs News Push Shares Up 13% Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access